Pfizer tests drug interactions in healthy volunteers
NCT ID NCT06837259
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how two common drugs—cyclosporine and clarithromycin—affect the levels of a new experimental medicine called PF-07328948 in the body. Twenty-six healthy adults received PF-07328948 alone and then with cyclosporine or clarithromycin. The goal was to understand drug interactions and safety, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07328948
- What this could lead to
- If successful, this study could help determine safe and effective dosing of PF-07328948 when taken with other drugs.
- What could go wrong
- This is a very early, small study in healthy volunteers, not patients. Results may not predict real-world effects or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, B-1070, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breakfast or fast? a trial puts Prifetrastat's absorption to the test
- Magic mushroom compound may rewire Self-Awareness — scientists put it to the test
- Can a phone app ease caregiver burnout? new study tests digital therapy
- Robotic hip brace may help control blood sugar after eating
- Smart knee brace and AI could revolutionize home rehab for arthritis
- Training the brain to hear and fix speech errors